The future of gene-targeted therapy for hereditary tyrosinemia type 1 as a lead indication among the inborn errors of metabolism

References

• Hansen K, Horslen S. Metabolic liver disease in children.Liver Transpl. 2008 [May];14(5):713–733.
   PubMed Web of Science ®Google Scholar
• Jalan AB. Treatment of inborn errors of metabolism. Mol Cytogenet. 2014;7(Suppl 1 Proceedings of the International Conference on Human):I42.
   PubMedGoogle Scholar
• Hegarty R, Hadzic N, Gissen P, et al. Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King’s college hospital experience. Eur J Pediatr. 2015 [Oct];174(10):1387–1392.
   PubMed Web of Science ®Google Scholar
• Zeybek AC, Kiykim E, Soyucen E, et al. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int. 2015 [Apr];57(2):281–289.
   PubMed Web of Science ®Google Scholar
• Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008 [Feb];31(1):81–87.
   PubMed Web of Science ®Google Scholar
• Al Hafid N, Christodoulou J. Phenylketonuria: a review of current and future treatments.Transl Pediatr. 2015 [Oct];4(4):304–317.
   PubMed Web of Science ®Google Scholar
• Belanger-Quintana A, Burlina A, Harding CO, et al. Up to date knowledge on different treatment strategies for phenylketonuria. Mol Genet Metab. 2011;104(Suppl):S19–25.
   PubMedGoogle Scholar
• Tanguay R. Hereditary tyrosinemia, pathogenesis, screening, and management. In: Tanguay R, editor. Advances in Experimental Medicine and Biology:. Vol. 1. Cham, Switzerland: Springer; 2017:5.
   Google Scholar
• Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia.Proc Natl Acad Sci USA. 1977 [Oct];74(10):4641–4645.
   PubMed Web of Science ®Google Scholar
• Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1.Semin Liver Dis. 2001 [Nov];21(4):563–571.
   PubMed Web of Science ®Google Scholar
• Endo F, Sun MS. Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells.J Inherit Metab Dis. 2002 [May];25(3):227–234.
   PubMed Web of Science ®Google Scholar
• Lock EA, Ellis MK, Gaskin P, et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis. 1998 [Aug];21(5):498–506.
   PubMed Web of Science ®Google Scholar
• Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab. 2012;107(1–2):49–54. Sep.
   PubMed Web of Science ®Google Scholar
• Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. J Inherit Metab Dis. 2012 [Mar];35(2):263–268.
   PubMed Web of Science ®Google Scholar
• Bendadi F, de Koning TJ, Visser G, et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. J Pediatr. 2014 [Feb];164(2):398–401.
   PubMed Web of Science ®Google Scholar
• van Spronsen FJ, Bijleveld CM, van Maldegem BT, et al. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr. 2005;40(1):90–93. Jan.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Jun 25]. Available from: www.drugbank.ca.
   Google Scholar
• van Ginkel WG, Rodenburg IL, Harding CO, et al. Long-term outcomes and practical considerations in the pharmacological management of Tyrosinemia Type 1. Paediatr Drugs. 2019 [Dec];21(6):413–426.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Jun 25]. Available from:www.nityr.us.
   Google Scholar
• Hjalmarson O, Holme E, Lindstedt S. NTBC therapy in Tyrosinemia Type I: long time results 114.Pediatr Res. 1996 [1996 September 01];40(3):534.
   Google Scholar
• Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis.Blood Adv. 2018 [Jul 24];2(14):1792–1798.
   PubMed Web of Science ®Google Scholar
• Chambers J, Silver MC, Lin PJ, et al. Cell and Gene therapies are associated with substantially larger quality-adjusted life year gains than conventional drugs and biologics. Value Health. 2019 [May];22:S263–S263.
   PubMed Web of Science ®Google Scholar
• Zabaleta N, Hommel M, Salas D, et al. Genetic-based approaches to inherited metabolic liver diseases. Hum Gene Ther. 2019 [Oct];30(10):1190–1203.
   PubMed Web of Science ®Google Scholar
• VanLith C, Kaiser RA, nicolas CT, et al. Ex vivo Gene therapy: a “cultured” surgical approach to curing inherited liver disease [Mini review]. OAJS. 2019 [2019 Mar 21];10(3):4.
   Google Scholar
• Grisch-Chan HM, Schwank G, Harding CO, et al. State-of-the-Art 2019 on Gene therapy for Phenylketonuria. Hum Gene Ther. 2019;30(10):1274-1283.
   Web of Science ®Google Scholar
• Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin deficiency.N Engl J Med. 2020 [Apr 9];382(15):1443–1455.
   PubMed Web of Science ®Google Scholar
• Overturf K, Al-Dhalimy M, Tanguay R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet. 1996;12(3):266–273. Mar.
   PubMed Web of Science ®Google Scholar
• Hickey RD, Mao SA, Glorioso J, et al. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Sci Transl Med. 2016;8(349):349ra99. Jul 27.
   PubMed Web of Science ®Google Scholar
• Hickey RD, Nicolas CT, Allen KL, et al. Autologous Gene and cell therapy provides safe and long-term curative therapy in a large Pig model of hereditary Tyrosinemia Type 1. Cell Transplant. 2019 Jan;28(1):79-88.
   PubMed Web of Science ®Google Scholar
• VanLith C, Guthman R, Nicolas CT, et al. Curative Ex Vivo Hepatocyte-directed Gene editing in a Mouse model of hereditary Tyrosinemia Type 1. Hum Gene Ther. 2018 [Nov];29(11):1315–1326.
   PubMed Web of Science ®Google Scholar
• Kaiser RA, Nicolas CT, Allen KL, et al. Hepatotoxicity and Toxicology of In Vivo Lentiviral vector administration in healthy and liver-injury Mouse models. Hum Genet Ther Clin Dev. 2019;30(2):57–66. Apr 11.
   PubMed Web of Science ®Google Scholar
• VanLith CJ, Guthman RM, Nicolas CT, et al. Ex Vivo Hepatocyte reprograming promotes homology-directed DNA repair to correct metabolic disease in Mice after transplantation. Hepatol Commun. 2019 [Apr];3(4):558–573.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015 [Feb];125(2):870–880.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.Blood. 2013 [Jul 4];122(1):23–36.
   PubMed Web of Science ®Google Scholar
• Colella P, Ronzitti G, Mingozzi F Emerging Issues in AAV-mediated In Vivo Gene therapy. Mol Ther Methods Clin Dev 2017 Dec 1;8:87–104.
   PubMed Web of Science ®Google Scholar
• Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 [Aug 23];341(6148):1233158.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013 [Aug 23];341(6148):1233151.
   PubMed Web of Science ®Google Scholar
• Rittelmeyer I, Rothe M, Brugman MH, et al. Hepatic lentiviral gene transfer is associated with clonal selection, but not with tumor formation in serially transplanted rodents. Hepatology. 2013 [Jul];58(1):397–408.
   PubMed Web of Science ®Google Scholar
• Visigalli I, Delai S, Ferro F, et al. Preclinical testing of the safety and tolerability of Lentiviral vector-mediated above-normal Alpha-L-Iduronidase expression in Murine and human Hematopoietic cells using toxicology and biodistribution good laboratory practice studies. Hum Gene Ther. 2016 [Oct];27(10):813–829.
   PubMed Web of Science ®Google Scholar
• Kaiser RA, Mao SA, Glorioso J, et al. Lentiviral vector-mediated gene therapy of hepatocytes Ex Vivo for autologous transplantation in Swine. J Vis Exp. 2018;141. Nov 4.
   Google Scholar
• Overturf K, Al-Dhalimy M, Manning K, et al. Ex vivo hepatic gene therapy of a mouse model of hereditary Tyrosinemia Type I. Hum Gene Ther. 1998 [Feb 10];9(3):295–304.
   PubMed Web of Science ®Google Scholar
• Nicolas CT, Hickey RD, Allen KL, et al. Hepatocyte spheroids as an alternative to single cells for transplantation after ex vivo gene therapy in mice and pig models. Surgery. 2018 [Sep];164(3):473–481.
   PubMed Web of Science ®Google Scholar
• Rossidis AC, Stratigis JD, Chadwick AC, et al. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat Med. 2018 [Oct];24(10):1513–1518.
   PubMed Web of Science ®Google Scholar
• Lee YM, Jun HS, Pan CJ, et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology. 2012 [Nov];56(5):1719–1729.
   PubMed Web of Science ®Google Scholar
• Ding Z, Harding CO, Rebuffat A, et al. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol Ther. 2008 [Apr];16(4):673–681.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, Tarasenko TN, Cusmano-Ozog K, et al. Liver-directed adeno-associated virus serotype 8 gene transfer rescues a lethal murine model of citrullinemia type 1. Gene Ther. 2013 [Dec];20(12):1188–1191.
   PubMed Web of Science ®Google Scholar
• Xie C, Gong XM, Luo J, et al. AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease. J Lipid Res. 2017 [Mar];58(3):512–518.
   PubMed Web of Science ®Google Scholar
• Chandler RJ, Williams IM, Gibson AL, et al. Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1. Hum Mol Genet. 2017 [Jan 1];26(1):52–64.
   PubMed Web of Science ®Google Scholar
• Salido E, Rodriguez-Pena M, Santana A, et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011 [May];19(5):870–875.
   PubMed Web of Science ®Google Scholar
• Zabaleta N, Barberia M, Martin-Higueras C, et al. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. Nat Commun. 2018 [Dec 21];9(1):5454.
   PubMedGoogle Scholar
• Senac JS, Chandler RJ, Sysol JR, et al. Gene therapy in a murine model of methylmalonic acidemia using rAAV9-mediated gene delivery. Gene Ther. 2012 [Apr];19(4):385–391.
   PubMed Web of Science ®Google Scholar
• Harrington EA, Sloan JL, Manoli I, et al. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia. Hum Gene Ther. 2016 [May];27(5):345–353.
   PubMed Web of Science ®Google Scholar
• An D, Schneller JL, Frassetto A, et al. Systemic messenger RNA therapy as a treatment for Methylmalonic Acidemia. Cell Rep. 2017 [Dec 19];21(12):3548–3558.
   PubMed Web of Science ®Google Scholar
• Kiyota T, Yamamoto M, Schroder B, et al. AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther. 2009 [May];17(5):803–809.
   PubMed Web of Science ®Google Scholar
• Kiyota T, Zhang G, Morrison CM, et al. AAV2/1 CD74 gene transfer reduces beta-amyloidosis and improves learning and memory in a Mouse model of Alzheimer’s disease. Mol Ther. 2015 [Nov];23(11):1712–1721.
   PubMed Web of Science ®Google Scholar
• Kanagawa M, Yu CC, Ito C, et al. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum Mol Genet. 2013 [Aug 1];22(15):3003–3015.
   PubMed Web of Science ®Google Scholar
• Yasuda M, Bishop DF, Fowkes M, et al. AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function. Mol Ther. 2010 [Jan];18(1):17–22.
   PubMed Web of Science ®Google Scholar
• Jiang L, Berraondo P, Jerico D, et al. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med. 2018 [Dec];24(12):1899–1909.
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Immune responses to AAV in clinical trials.Curr Gene Ther. 2011 [Aug];11(4):321–330.
   PubMed Web of Science ®Google Scholar
• Cantore A, Ranzani M, Bartholomae CC, et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med. 2015 Mar 4;7(277):277ra28.
   PubMed Web of Science ®Google Scholar
• Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.Gene Ther. 2004 [Oct];11(Suppl 1):S10–7.
   PubMedGoogle Scholar
• Tran ND, Porada CD, Almeida-Porada G, et al. Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. Blood. 2001 [Jun 1];97(11):3417–3423.
   PubMed Web of Science ®Google Scholar
• Himmelreich N, Shen N, Okun JG, et al. Relationship between genotype, phenylalanine hydroxylase expression and in vitro activity and metabolic phenotype in phenylketonuria. Mol Genet Metab. 2018 [Sep];125(1–2):86–95.
   PubMed Web of Science ®Google Scholar
• Jiang W, Liu L, Chang Q, et al. Production of Wilson disease model Rabbits with homology-directed precision point mutations in the ATP7B gene using the CRISPR/Cas9 system. Sci Rep. 2018 [Jan 22];8(1):1332.
   PubMedGoogle Scholar
• Roybal JL, Endo M, Radu A, et al. Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson’s disease. Gene Ther. 2012 [Nov];19(11):1085–1094.
   PubMed Web of Science ®Google Scholar
• Murillo O, Luqui DM, Gazquez C, et al. Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy. J Hepatol. 2016 [Feb];64(2):419–426.
   PubMed Web of Science ®Google Scholar
• Wang L, Takabe K, Bidlingmaier SM, et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A. 1999 [Mar 30];96(7):3906–3910.
   PubMed Web of Science ®Google Scholar
• Grimm D, Zhou S, Nakai H, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003 [Oct 1];102(7):2412–2419.
   PubMed Web of Science ®Google Scholar
• Yamada T, Iwasaki Y, Tada H, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003 [Aug];21(8):885–890.
   PubMed Web of Science ®Google Scholar
• Chen J, Guo Z, Tian H, et al. Production and clinical development of nanoparticles for gene delivery. Mol Ther Methods Clin Dev. 2016;3:16023.
   PubMed Web of Science ®Google Scholar
• Yin H, Song CQ, Dorkin JR, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016 [Mar];34(3):328–333.
   PubMed Web of Science ®Google Scholar
• Santillan-Doherty P, Grether-Gonzalez P, Medina-Arellano MJ, et al. Considerations on genetic engineering: regarding the birth of twins subjected to gene edition. Gac Med Mex. 2020;156(1):53–59.
   PubMed Web of Science ®Google Scholar
• Schiroli G, Conti A, Ferrari S, et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell. 2019 [Apr 4];24(4):551–565 e8.
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII gene transfer in severe Hemophilia A. N Engl J Med. 2017 [Dec 28];377(26):2519–2530.
   PubMed Web of Science ®Google Scholar
• Hamman K, Clark H, Montini E, et al. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Mol Ther. 2005 [Aug];12(2):337–344.
   PubMed Web of Science ®Google Scholar
• Grompe M, Overturf K, al-Dhalimy M, et al. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report. J Inherit Metab Dis. 1998 [Aug];21(5):518–531.
   PubMed Web of Science ®Google Scholar
• Al-Dhalimy M, Overturf K, Finegold M, et al. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab. 2002 [Jan];75(1):38–45.
   PubMed Web of Science ®Google Scholar
• Gokay S, Ustkoyuncu PS, Kardas F, et al. The outcome of seven patients with hereditary tyrosinemia type 1. J Pediatr Endocrinol Metab. 2016 [Oct 1];29(10):1151–1157.
   PubMed Web of Science ®Google Scholar
• Gerets HH, Tilmant K, Gerin B, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 [Apr];28(2):69–87.
   PubMed Web of Science ®Google Scholar
• Hickey RD, Nicolas CT, Allen K, et al. Autologous gene and cell therapy provides safe and long-term curative therapy in a large Pig model of hereditary Tyrosinemia Type 1. Cell Transplant. 2019 [Jan];28(1):79–88.
   PubMed Web of Science ®Google Scholar